KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Other Non-Current Liabilities: 2009-2025

Historic Other Non-Current Liabilities for Acadia Pharmaceuticals (ACAD) over the last 10 years, with Sep 2025 value amounting to $13.9 million.

  • Acadia Pharmaceuticals' Other Non-Current Liabilities fell 9.35% to $13.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year decrease of 9.35%. This contributed to the annual value of $18.1 million for FY2024, which is 19.21% up from last year.
  • As of Q3 2025, Acadia Pharmaceuticals' Other Non-Current Liabilities stood at $13.9 million, which was down 51.35% from $28.5 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $28.5 million for Q2 2025, and its period low was $3.6 million during Q1 2021.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $13.9 million (2025), whereas its average is $14.7 million.
  • Data for Acadia Pharmaceuticals' Other Non-Current Liabilities shows a peak YoY increase of 130.93% (in 2025) and a maximum YoY decrease of 9.35% (in 2025) over the last 5 years.
  • Over the past 5 years, Acadia Pharmaceuticals' Other Non-Current Liabilities (Quarterly) stood at $7.0 million in 2021, then grew by 29.00% to $9.1 million in 2022, then soared by 66.93% to $15.1 million in 2023, then climbed by 19.21% to $18.1 million in 2024, then dropped by 9.35% to $13.9 million in 2025.
  • Its Other Non-Current Liabilities was $13.9 million in Q3 2025, compared to $28.5 million in Q2 2025 and $20.0 million in Q1 2025.